tiprankstipranks
Talaris Therapeutics to suspend further guidance on status of programs
The Fly

Talaris Therapeutics to suspend further guidance on status of programs

As the Company assesses strategic alternatives, it will suspend further guidance on the status of its programs. As of December 31, 2022, the Company’s cash, cash equivalents and short- and long-term marketable securities were approximately $181.3 million.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles